Whether combined with genotoxic therapy or provided on their own, STING agonists have the potential to enhance antitumor responses [151] and have demonstrated encouraging activity in HNSCC [152,153,154,155,156,157], including in HPV+ tumors where STING may be targeted by the E7 viral protein [158]. Here, STING1 is linked to head and neck squamous cell carcinoma.